Open AccessThe Status of Humoral Immunity to Parvovirus B19 in Population of Certain Geographical Regions
Author(s) -
И. Н. Лаврентьева,
Irina V. Khamitova,
Jacob Camara,
Анастасия Юрьевна Антипова,
Маина Александровна Бичурина,
Faly N. Magassouba,
О. Н. Никишов,
А. А. Кузин,
Александр Владимирович Семенов
Publication year - 2020
Publication title -
žurnal mikrobiologii, èpidemiologii i immunobiologii
Language(s) - English
Resource type - Journals
eISSN - 2686-7613
pISSN - 0372-9311
DOI - 10.36233/0372-9311-2020-97-3-5
Subject(s) - seroprevalence , parvovirus , demography , population , medicine , geography , immunology , antibody , environmental health , serology , virus , sociology
. In a number of countries, including Russia, there is no systematic registration and reporting of parvovirus infection cases; the extent of its spread can be estimated by using humoral immunity rates. Purpose of the study : Assessment of seroprevalence of parvovirus B19 (B19V) in different age groups of population of Russia, Central Asia, and West Africa. Materials and methods . A total of 1,732 blood serum samples from residents of St. Petersburg and Nur-Sultan, migrant workers from Uzbekistan and Tajikistan, residents of the Republic of Guinea were studied for IgG antibodies to B19V. Results . The highest seroprevalence rates were identified in St. Petersburg and Nur-Sultan (62–65%); the lowest rates were registered among migrant workers from Uzbekistan and Tajikistan (47%). The results for the Republic of Guinea showed a B19V seroprevalence rate of 53%. It was found that there is an increasing trend of seropositivity with age; the percentage of seropositive individuals clearly increases in older age groups: up to 55% — among migrant workers from Central Asia and residents of the Republic of Guinea; up to 80–85% — among residents of St. Petersburg and Nur-Sultan. Discussion . The obtained results confirm the worldwide occurrence of parvovirus infection. People susceptible to infection can cause infection spreading in high-risk groups — among pregnant women, immunodeficient patients, blood product recipients, and cancer patients.